WHO MOC
There was a significant treatment benefit for patients receiving nebulised UFH on top of standard of care versus patients treated with standard of care only as assessed by the WHO MOCS (Table 7). At day 29, the treatment difference reached significance in all analysis populations (p<0.1).
Table 6 – Evolution of the MOOC WHO scale following treatment with standard of care or heparin plus standard of care